Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

In a study comparing treatments for type 2 diabetes, SGLT2 inhibitors show double the risk of ketoacidosis versus gliptins

Researchers found that the risk of diabetic ketoacidosis by day 180 was double in patients who initiated SGLT2 inhibitors compared with those who received DPP4 inhibitors.

Source  Shutterstock.com